Soligenix (SNGX.OB) is an up and coming biotech company with a large pipeline focusing on bio-therapeutic pharmaceuticals as well as bioterrorist/bio-warfare vaccines and treatments. In my last article on Soligenix we took a look at the company's current product pipeline and near-term catalysts. Since then SNGX has been picked up by Zack's Investment research and issued a "Buy" with a $4.50 price target over the next 1-3 months. As well the company has secured a new $7.1M in capital and is continuing to push full force ahead into new 2013/2014 catalysts. In this article we will take a look at the current upcoming trial milestones, partnerships and insider activity, which could be signaling investors to take a...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|